Inhibition of transient lower esophageal sphincter relaxation in GERD: will lesogaberan advance the field?
Falk
Gary W
GW
D004359:Drug Therapy, Combination; D049631:Esophageal Sphincter, Upper / Q000187:drug effects* / Q000503:physiopathology; D018755:GABA Agonists / Q000627:therapeutic use*; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D009126:Muscle Relaxation / Q000187:drug effects*; D010721:Phosphinic Acids / Q000627:therapeutic use*; D011312:Pressure; D011437:Propylamines / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D018755:GABA Agonists; D010721:Phosphinic Acids; D011437:Propylamines; D054328:Proton Pump Inhibitors; C545087:lesogaberan